vs
BIOMERICA INC（BMRA）与NEOGEN CORP（NEOG）财务数据对比。点击上方公司名可切换其他公司
NEOGEN CORP的季度营收约是BIOMERICA INC的185.7倍（$224.7M vs $1.2M）。NEOGEN CORP净利率更高（-7.1% vs -109.1%，领先102.0%）。NEOGEN CORP同比增速更快（-2.8% vs -26.0%）。过去两年BIOMERICA INC的营收复合增速更高（9.1% vs -0.9%）
Biomerica Inc.是一家全球性医疗技术企业，研发、生产及销售诊断检测试剂盒与相关医疗产品，产品线覆盖胃肠疾病、传染病、食物不耐受检测及即时检测解决方案，服务全球多地的临床实验室、医疗机构及零售医疗客户。
Neogen Corporation是一家1982年成立、总部位于美国密歇根州兰辛的跨国食品安全企业，专注提供各类检测试剂盒及相关产品，用于筛查食品中的有害成分。目前业务覆盖美国、加拿大、英国、欧洲部分地区、墨西哥、巴西、印度、中国等多个国家，旗下拥有超100款药物检测试剂盒产品，可检测约300种相关违禁物质。
BMRA vs NEOG — 直观对比
营收规模更大
NEOG
是对方的185.7倍
$1.2M
营收增速更快
NEOG
高出23.2%
-26.0%
净利率更高
NEOG
高出102.0%
-109.1%
两年增速更快
BMRA
近两年复合增速
-0.9%
损益表 — Q2 2026 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $224.7M |
| 净利润 | $-1.3M | $-15.9M |
| 毛利率 | 4.2% | 47.5% |
| 营业利润率 | -113.5% | -2.4% |
| 净利率 | -109.1% | -7.1% |
| 营收同比 | -26.0% | -2.8% |
| 净利润同比 | -38.9% | 96.5% |
| 每股收益（稀释后） | $-0.45 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRANEOG
| Q4 25 | $1.2M | $224.7M | ||
| Q3 25 | $1.4M | $209.2M | ||
| Q2 25 | $749.0K | $225.4M | ||
| Q1 25 | $1.1M | $221.0M | ||
| Q4 24 | $1.6M | $231.3M | ||
| Q3 24 | $1.8M | $217.0M | ||
| Q2 24 | $1.1M | $236.8M | ||
| Q1 24 | $1.0M | $228.8M |
净利润BMRANEOG
| Q4 25 | $-1.3M | $-15.9M | ||
| Q3 25 | $2.0K | $36.3M | ||
| Q2 25 | $-1.5M | $-612.3M | ||
| Q1 25 | $-1.2M | $-10.9M | ||
| Q4 24 | $-950.0K | $-456.3M | ||
| Q3 24 | $-1.3M | $-12.6M | ||
| Q2 24 | $-1.4M | $-5.4M | ||
| Q1 24 | $-1.9M | $-2.0M |
毛利率BMRANEOG
| Q4 25 | 4.2% | 47.5% | ||
| Q3 25 | 30.7% | 45.4% | ||
| Q2 25 | -33.0% | 41.2% | ||
| Q1 25 | 1.7% | 49.9% | ||
| Q4 24 | 26.7% | 49.0% | ||
| Q3 24 | 16.0% | 48.4% | ||
| Q2 24 | 2.1% | 47.9% | ||
| Q1 24 | -14.7% | 51.1% |
营业利润率BMRANEOG
| Q4 25 | -113.5% | -2.4% | ||
| Q3 25 | -81.0% | -7.7% | ||
| Q2 25 | -209.1% | -271.1% | ||
| Q1 25 | -108.1% | 2.4% | ||
| Q4 24 | -60.7% | -197.8% | ||
| Q3 24 | -75.7% | 1.0% | ||
| Q2 24 | -136.6% | 5.5% | ||
| Q1 24 | -196.7% | 5.3% |
净利率BMRANEOG
| Q4 25 | -109.1% | -7.1% | ||
| Q3 25 | 0.1% | 17.4% | ||
| Q2 25 | -206.1% | -271.6% | ||
| Q1 25 | -103.9% | -4.9% | ||
| Q4 24 | -58.1% | -197.3% | ||
| Q3 24 | -72.8% | -5.8% | ||
| Q2 24 | -127.1% | -2.3% | ||
| Q1 24 | -188.6% | -0.9% |
每股收益（稀释后）BMRANEOG
| Q4 25 | $-0.45 | $-0.07 | ||
| Q3 25 | $0.00 | $0.17 | ||
| Q2 25 | $-0.99 | $-2.82 | ||
| Q1 25 | $-0.48 | $-0.05 | ||
| Q4 24 | $-0.06 | $-2.10 | ||
| Q3 24 | $-0.63 | $-0.06 | ||
| Q2 24 | $-2.57 | $-0.02 | ||
| Q1 24 | $-0.11 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $145.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.4M | $2.1B |
| 总资产 | $6.0M | $3.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRANEOG
| Q4 25 | $2.5M | $145.3M | ||
| Q3 25 | $3.1M | $138.9M | ||
| Q2 25 | $3.1M | $129.0M | ||
| Q1 25 | $3.1M | $127.7M | ||
| Q4 24 | $2.4M | $140.2M | ||
| Q3 24 | $2.8M | $120.5M | ||
| Q2 24 | $4.2M | $170.9M | ||
| Q1 24 | $5.3M | $168.4M |
股东权益BMRANEOG
| Q4 25 | $4.4M | $2.1B | ||
| Q3 25 | $5.2M | $2.1B | ||
| Q2 25 | $4.1M | $2.1B | ||
| Q1 25 | $5.5M | $2.7B | ||
| Q4 24 | $5.1M | $2.7B | ||
| Q3 24 | $5.3M | $3.1B | ||
| Q2 24 | $6.6M | $3.1B | ||
| Q1 24 | $7.8M | $3.1B |
总资产BMRANEOG
| Q4 25 | $6.0M | $3.4B | ||
| Q3 25 | $6.9M | $3.4B | ||
| Q2 25 | $5.9M | $3.4B | ||
| Q1 25 | $7.4M | $4.0B | ||
| Q4 24 | $7.3M | $4.1B | ||
| Q3 24 | $7.9M | $4.5B | ||
| Q2 24 | $9.3M | $4.5B | ||
| Q1 24 | $10.3M | $4.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-991.0K | $19.4M |
| 自由现金流经营现金流 - 资本支出 | — | $7.8M |
| 自由现金流率自由现金流/营收 | — | 3.5% |
| 资本支出强度资本支出/营收 | — | 5.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-18.5M |
8季度趋势，按日历期对齐
经营现金流BMRANEOG
| Q4 25 | $-991.0K | $19.4M | ||
| Q3 25 | $-268.0K | $10.9M | ||
| Q2 25 | $-661.0K | $16.4M | ||
| Q1 25 | $-1.0M | $19.5M | ||
| Q4 24 | $-791.0K | $40.3M | ||
| Q3 24 | $-1.3M | $-17.9M | ||
| Q2 24 | $-1.0M | $26.7M | ||
| Q1 24 | $-1.8M | $-30.2M |
自由现金流BMRANEOG
| Q4 25 | — | $7.8M | ||
| Q3 25 | — | $-13.1M | ||
| Q2 25 | — | $349.0K | ||
| Q1 25 | — | $-13.4M | ||
| Q4 24 | — | $23.1M | ||
| Q3 24 | — | $-56.3M | ||
| Q2 24 | $-1.1M | $2.5M | ||
| Q1 24 | — | $-62.3M |
自由现金流率BMRANEOG
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | -6.3% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | -6.1% | ||
| Q4 24 | — | 10.0% | ||
| Q3 24 | — | -26.0% | ||
| Q2 24 | -95.5% | 1.1% | ||
| Q1 24 | — | -27.2% |
资本支出强度BMRANEOG
| Q4 25 | — | 5.2% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | — | 7.1% | ||
| Q1 25 | — | 14.9% | ||
| Q4 24 | — | 7.4% | ||
| Q3 24 | — | 17.7% | ||
| Q2 24 | 2.1% | 10.2% | ||
| Q1 24 | 0.0% | 14.0% |
现金转化率BMRANEOG
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | 0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRA
暂无分部数据
NEOG
| Other | $109.2M | 49% |
| Bacterial And General Sanitation | $44.9M | 20% |
| Services | $25.7M | 11% |
| Natural Toxins And Allergens | $20.4M | 9% |
| Animal Care | $8.9M | 4% |
| Genomics Services | $6.3M | 3% |
| Biosecurity Products | $4.6M | 2% |
| Life Sciences | $1.4M | 1% |
